Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 39, Issue 2, 2001, Pages 61-66

  Krueger, M ^a   Achenbach, H ^a   Terhaag, B ^a   Haase, H ^a   Richter, K ^a   Oertel, R ^a   Preiss, R ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Hemodialysis; Pharmacokinetics; Renal impairment; Talinolol

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; GLYCOPROTEIN; LIPID; TALINOLOL;

ADULT; ARTICLE; BLOOD ANALYSIS; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIALYSATE; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG URINE LEVEL; GASTROINTESTINAL ABSORPTION; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION TEST; STEADY STATE; URINALYSIS; URINARY EXCRETION; VOLUNTEER;

EID: 0035105191     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP39061     Document Type: Article

References (22)

1. Influence of renal function on the pharmacokinetics of diacerein after a single oral dose
2. Serum alpha-1-acid glycoprotein in chronic renal failure
3. Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker talinolol in humans
4. Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients
5. Pharmacokinetics of abecarnil in patients with renal insufficiency
6. Principles of drug administration in renal insufficiency
7. Grapefruit juice components modify the intestinal permeability of the p-glycoprotein substrate talinolol
8. Elucidation of the structure of talinolol metabolites in man. Determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum
9. Effects of hemodialysis on plasma protein binding of bepridil
10. Alteration of drug-protein binding in renal disease
11. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans
12. The erythromycin-talinolol interaction increases oral bioavailability in humans
13. P-Glycoprotein transporters and the gastrointestinal tract: Evaluation the potential in vivo relevance of in vitro data employing talinolol as model compound
14. The biliary elimination of the selective β-receptor blocking drug talinolol in man
15. Zur Effektivität der Hämoperfusion bei einer Talinolol-Intoxikation - Ein Fallbericht
16. Zur Pharmakokinetik von Talinolol (Cordanum) nach wiederholter 7tägiger oraler Gabe am gesunden Probanden
17. The effect of renal failure on hepatic drug clearance
18. 1-adrenoceptor antagonist talinolol in man
19. Talinolol-Rifampicin interaction: Potential role of drug transporters
20. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: Concentration- and dose-dependent absorption in vitro and in vivo
21. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs